Pubertal induction in girls with Turner Syndrome.


Journal

Minerva endocrinology
ISSN: 2724-6116
Titre abrégé: Minerva Endocrinol (Torino)
Pays: Italy
ID NLM: 101777342

Informations de publication

Date de publication:
12 2021
Historique:
pubmed: 14 1 2021
medline: 28 1 2022
entrez: 13 1 2021
Statut: ppublish

Résumé

Turner Syndrome (TS) is the most common female sex chromosome aneuploidy in females, and patients may present with hypergonadotropic hypogonadism due to gonadal dysgenesis. Timing and modalities of pubertal induction in these patients is still a matter of debate. Aim of this review was to focus on the latest update on pubertal induction in TS. Based on literature data, the following practical approach to this issue is recommended. Pubertal induction should begin between 11 and 12 years of age, starting with low doses of estradiol to preserve height potential. Transdermal 17β-Estradiol (17β-E2) could represent the first-choice induction regimen as it is more physiologic compared to an oral regimen and avoids the first-pass mechanism in the liver. In the case of poor compliance, administration of oral 17β-E2 or ethinyl estradiol could be offered. Incremental dose increases, approximately every 6 months, can contribute to mimic normal pubertal progression until adult dosing is reached over a 2- to 3-year period. Progestin should be added once breakthrough bleeding occurs or after 2 to 3 years of estrogen therapy or if ultrasound shows a mature uterus with thick endometrium. Treatment needs to be individualized and monitored by clinical assessment in relation to patient compliance and satisfaction. Well-designed prospective randomized clinical trials aimed to identify the best estrogen regimen for pubertal induction in TS girls are needed.

Identifiants

pubmed: 33435643
pii: S0391-1977.20.03285-X
doi: 10.23736/S2724-6507.20.03285-X
doi:

Substances chimiques

Estrogens 0
Estradiol 4TI98Z838E

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

469-480

Auteurs

Tommaso Aversa (T)

Department of Human Pathology in Adulthood and Childhood, University of Messina, Messina, Italy - taversa@unime.it.

Domenico Corica (D)

Department of Human Pathology in Adulthood and Childhood, University of Messina, Messina, Italy.

Giorgia Pepe (G)

Department of Human Pathology in Adulthood and Childhood, University of Messina, Messina, Italy.

Giovanni B Pajno (GB)

Department of Human Pathology in Adulthood and Childhood, University of Messina, Messina, Italy.

Mariella Valenzise (M)

Department of Human Pathology in Adulthood and Childhood, University of Messina, Messina, Italy.

Maria F Messina (MF)

Department of Human Pathology in Adulthood and Childhood, University of Messina, Messina, Italy.

Malgorzata Wasniewska (M)

Department of Human Pathology in Adulthood and Childhood, University of Messina, Messina, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH